rp-1,vusolimogene,nivolumab,rp2
bms,replimune
['rp2 ', 'rp1', 'melanoma', 'ignyte', '$repl', 'replimune']
$repl replimune presents rp1 data from the ignyte anti-pd1 failed melanoma cohort and rp2 data in uveal melanoma at the 2023 american society of clinical oncology (asco) annual meeting 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities